Drug intelligence / Profile preview

AS1801

Development stage: Unknown
Lead developer: Zhongke Aishen Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

AS1801 is a proprietary nucleic acid nano-delivery platform developed by **Zhongke Aishen Pharmaceutical** (also known as Amshenn). The technology is specifically engineered to enable the targeted delivery of nucleic acid therapeutics, such as siRNA or mRNA, to immune cells. By utilizing nanotechnology to overcome delivery barriers, AS1801 aims to modulate immune responses for the treatment of cancer and inflammatory diseases. As a platform technology, it serves as the foundation for multiple therapeutic programs within the company's pipeline, focusing on enhancing the precision and efficacy of immunotherapies while minimizing systemic off-target effects.

Other names: Nucleic acid nano-delivery platform

Beyond the preview

Go deeper on AS1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS1801.

Explore the full profile